INO
Inovio Pharmaceuticals, Inc.Company with tickers: INO
CIK
1055726
CUSIP
45773H409
Shares Outstanding
82,273,237
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $65,343 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $25,115,872 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $16,090,902 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-25,050,529 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-19,694,697 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.51 | USD/shares | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.51 | USD/shares | 2025-03-31 | 10-Q | 2026-05-13 |